M. Braun

发表

Elucidating pretreatment cognitive impairment in breast cancer patients: the impact of cancer-related post-traumatic stress.

M. Bühner, N. Harbeck, I. Bauerfeind, 2015, Journal of the National Cancer Institute.

Influence of preoperative MRI on the surgical management of patients with operable breast cancer

Christiane K. Kuhl, Simone Schrading, Uta Flucke, 2007, Breast Cancer Research and Treatment.

Irradiated breast cancer patients demonstrate subgroup-specific regularities in protein expression patterns of circulating leukocytes.

H. Schild, O. Golubnitschaja, K. Yeghiazaryan, 2007, Cancer genomics & proteomics.

Endocrine Therapy Response and 21-Gene Expression Assay for Therapy Guidance in HR+/HER2– Early Breast Cancer

S. Shak, F. Baehner, N. Harbeck, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Outcome of breast cancer patients with low hormone receptor positivity: Analysis of a 15-year population-based cohort.

W. Weichert, C. Denkert, M. Kiechle, 2021, Annals of oncology : official journal of the European Society for Medical Oncology.

Primary Therapy of Early Breast Cancer: Evidence, Controversies, Consensus

P. Fasching, A. Schneeweiss, T. Kühn, 2019, Geburtshilfe und Frauenheilkunde.

Impact of the menstrual cycle on circulating cell-free DNA.

T. Höller, O. el-Maarri, W. Kuhn, 2010, Anticancer research.

Recent Developments in Radiation Oncology: An Overview of Individualised Treatment Strategies in Breast Cancer

N. Harbeck, C. Belka, F. Alongi, 2018, Breast Care.

Chemotherapy and Post-traumatic Stress in the Causation of Cognitive Dysfunction in Breast Cancer Patients

M. Bühner, N. Harbeck, I. Bauerfeind, 2017, Journal of the National Cancer Institute.

Staging of Primary Breast Cancer Is not Indicated in Asymptomatic Patients with Early Tumor Stages

C. Leutner, T. Höller, W. Kuhn, 2014, Oncology Research and Treatment.

ESCP 37th European Symposium on Clinical Pharmacy, Pharmaceutical Care Models, and Therapeutic Innovations, Dubrovnik, Croatia, 21–24 October 2008

W. Kuhn, U. Jaehde, P. Rosset, 2008, Pharmacy World & Science.

Detection of Lymphovascular Invasion in Vulvar Cancer by D2-40 (Podoplanin) as a Predictor for Inguinal Lymph Node Metastases

E. Wardelmann, T. Höller, R. Büttner, 2009, Oncology Research and Treatment.

Foxp3+ cell infiltration and granzyme B+/Foxp3+ cell ratio are associated with outcome in neoadjuvant chemotherapy-treated ovarian carcinoma

R. Fimmers, R. Büttner, W. Kuhn, 2010, Cancer Immunology, Immunotherapy.

Down-regulation of microfilamental network-associated proteins in leukocytes of breast cancer patients: potential application to predictive diagnosis.

H. Schild, T. Höller, W. Kuhn, 2009, Cancer genomics & proteomics.

Role of postoperative radiotherapy in reducing ipsilateral recurrence in DCIS: an observational study of 1048 cases

N. Harbeck, C. Belka, S. Corradini, 2018, Radiation Oncology.

Does deep inspiration breath-hold prolong life? Individual risk estimates of ischaemic heart disease after breast cancer radiotherapy.

N. Harbeck, C. Belka, S. Corradini, 2019, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Trends in use and outcome of postoperative radiotherapy following mastectomy: A population-based study.

M. Kiechle, N. Harbeck, I. Bauerfeind, 2017, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Impact of stromal tumor-infiltrating lymphocytes (sTILs) on response to neoadjuvant chemotherapy in triple-negative early breast cancer in the WSG-ADAPT TN trial

F. Feuerhake, N. Harbeck, O. Gluz, 2022, Breast cancer research : BCR.

Does deep inspiration breath-hold prolong life? Individual risk estimates of ischaemic heart disease after breast cancer radiotherapy.

N. Harbeck, C. Belka, S. Corradini, 2018, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Abstract S5-03: Final analysis of WSG-ADAPT HER2+/HR+ phase II trial: Efficacy, safety, and predictive markers for 12-weeks of neoadjuvant TDM1 with or without endocrine therapy versus trastuzumab+endocrine therapy in HER2-positive hormone-receptor-positive early breast cancer

N. Harbeck, O. Gluz, S. Kuemmel, 2016 .

Final analysis of WSG-ADAPT HER2+/HR+ phase-II-trial - efficacy, safety and predictive markers for 12-weeks of neoadjuvant T-DM1 with or without endocrine therapy versus Trastuzumab plus endocrine therapy in HER2-positive hormone-receptor-positive early breast cancer

O. Gluz, S. Kuemmel, C. Liedtke, 2016 .

Comparison of Neoadjuvant Nab-Paclitaxel+Carboplatin vs Nab-Paclitaxel+Gemcitabine in Triple-Negative Breast Cancer: Randomized WSG-ADAPT-TN Trial Results

N. Harbeck, O. Gluz, S. Kuemmel, 2018, Journal of the National Cancer Institute.

Vaccination with dendritic cells transfected with mRNA-encoded folate-receptor-alpha for relapsed metastatic ovarian cancer.

C. Leutner, W. Kuhn, H. Fischer, 2007, The Lancet. Oncology.

De-escalation strategies in HER2-positive early breast cancer (EBC): final analysis of the WSG-ADAPT HER2+/HR- phase II trial: efficacy, safety, and predictive markers for 12weeks of neoadjuvant dual blockade with trastuzumab and pertuzumab ± weekly paclitaxel.

N. Harbeck, O. Gluz, S. Kuemmel, 2017 .

De-escalated neoadjuvant pertuzumab plus trastuzumab therapy with or without weekly paclitaxel in HER2-positive, hormone receptor-negative, early breast cancer (WSG-ADAPT-HER2+/HR-): survival outcomes from a multicentre, open-label, randomised, phase 2 trial.

N. Harbeck, O. Gluz, S. Kuemmel, 2022, The Lancet. Oncology.

Validation of the 21-Gene Recurrence Score Assay in Patients with Hormone Receptor-Positive, HER2-Negative Breast Cancer and 0 to 3 Positive Lymph Nodes: Risk Pattern and Outcomes on a Community Level

C. Hanusch, O. Stoetzer, M. Kriner, 2021, Breast Care.

De-escalation strategies in HER2-positive early breast cancer (EBC): final analysis of the WSG-ADAPT HER2+/HR− phase II trial efficacy, safety, and predictive markers for 12 weeks of neoadjuvant dual blockade with trastuzumab and pertuzumab ± weekly paclitaxel

N. Harbeck, O. Gluz, S. Kuemmel, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Treatment of Early Breast Cancer Patients: Evidence, Controversies, Consensus: Focusing on Systemic Therapy – German Experts’ Opinions for the 16th International St. Gallen Consensus Conference (Vienna 2019)

P. Fasching, A. Schneeweiss, T. Kühn, 2019, Breast Care.

Clinically assessed posttraumatic stress in patients with breast cancer during the first year after diagnosis in the prospective, longitudinal, controlled COGNICARES study

M. Bühner, N. Harbeck, I. Bauerfeind, 2017, Psycho-oncology.

Noninvasive subcellular imaging in breast cancer risk assessment: construction of diagnostic windows.

H. Schild, W. Kuhn, O. Golubnitschaja, 2011, Personalized medicine.

Treatment with Combinations of the Anti-HER2 Antibody Trastuzumab and Capecitabine in Advanced Metastatic Breast Cancer Patients – a Pilot Study

C. Rudlowski, M. Braun, A. Faridi, 2007, Breast Care.

Detection of Lymphovascular Invasion by D2-40 (Podoplanin) Immunoexpression in Endometrial Cancer

W. Kuhn, C. Rudlowski, M. Braun, 2012, International Journal of Gynecologic Cancer.

Magnetic resonance imaging and ultrasound for prediction of residual tumor size in early breast cancer within the ADAPT subtrials

C. Herzog, C. Kuhl, A. Frydrychowicz, 2020, Breast Cancer Research.

Efficacy of 12 weeks neoadjuvant nab-paclitaxel combined with carboplatinum vs. gemcitabine in triple-negative breast cancer: WSG-ADAPT TN randomized phase II trial.

N. Harbeck, O. Gluz, C. Liedtke, 2015 .

Immune cell composition and functional marker dynamics from multiplexed immunohistochemistry to predict response to neoadjuvant chemotherapy in the WSG-ADAPT-TN trial

F. Feuerhake, M. Hauptmann, N. Harbeck, 2021, Journal for ImmunoTherapy of Cancer.

Risk assessment, disease prevention and personalised treatments in breast cancer: is clinically qualified integrative approach in the horizon?

H. Schild, W. Kuhn, O. Golubnitschaja, 2013, EPMA Journal.

Identification of specific nuclear structural protein alterations in human breast cancer

K. Walgenbach, G. Hartmann, W. Kuhn, 2011, Journal of cellular biochemistry.

TP53 mutations are associated with primary endocrine resistance in luminal early breast cancer

N. Harbeck, O. Gluz, S. Kuemmel, 2021, Cancer medicine.

The run-in phase of the prospective WSG-ADAPT HR+/HER2– trial demonstrates the feasibility of a study design combining static and dynamic biomarker assessments for individualized therapy in early breast cancer

S. Shak, F. Baehner, N. Harbeck, 2020, Therapeutic advances in medical oncology.

A randomised, open-label phase II trial of afatinib versus cetuximab in patients with metastatic colorectal cancer.

T. Hickish, J. Cassidy, I. Macpherson, 2014, European journal of cancer.

Prediction and prognosis: impact of gene expression profiling in personalized treatment of breast cancer patients

W. Kuhn, M. Mallmann, J. Schultze, 2010, EPMA Journal.

Efficacy of deescalated chemotherapy according to PAM50 subtypes, immune and proliferation genes in triple‐negative early breast cancer: Primary translational analysis of the WSG‐ADAPT‐TN trial

N. Harbeck, O. Gluz, S. Kuemmel, 2019, International journal of cancer.

Prevalence of BRCA1/2 germline mutations in 21 401 families with breast and ovarian cancer

Tanja Fehm, Nina Ditsch, Dieter Niederacher, 2016, Journal of Medical Genetics.

Risk assessment, disease prevention and personalised treatments in breast cancer: is clinically qualified integrative approach in the horizon?

H. Schild, W. Kuhn, O. Golubnitschaja, 2013, EPMA Journal.

Circulating Cell Free DNA as Blood Based Biomarker in Breast Cancer

Stefan Holdenrieder, S. Holdenrieder, O. Stötzer, 2014 .

Detection of lymphovascular invasion in early breast cancer by D2-40 (podoplanin): a clinically useful predictor for axillary lymph node metastases

K. Walgenbach, T. Höller, R. Büttner, 2008, Breast Cancer Research and Treatment.

The use of breast ultrasound for prediction of pathologic complete response in different subtypes of early breast cancer within the WSG-ADAPT subtrials

N. Harbeck, O. Gluz, S. Kümmel, 2021, Breast.

Early response by MR imaging and ultrasound as predictor of pathologic complete response to 12‐week neoadjuvant therapy for different early breast cancer subtypes: Combined analysis from the WSG ADAPT subtrials

C. Kuhl, N. Harbeck, O. Gluz, 2021, International journal of cancer.

Non-invasive proteomics—thinking about personalized breast cancer screening and treatment

W. Kuhn, M. Braun, G. Walgenbach-Brünagel, 2010, EPMA Journal.

Oncotype DX and proliferation response to short-term preoperative endocrine therapy for chemotherapy decision in early breast cancer: Biomarker data from the prospective multicenter phase II/III WSG-ADAPT trial.

M. Rezai, S. Shak, N. Harbeck, 2014 .

ADAPTcycle: Adjuvant dynamic marker-adjusted personalized therapy (ADAPT) comparing endocrine therapy plus ribociclib versus chemotherapy in intermediate-risk HR+/HER2- early breast cancer (EBC).

N. Harbeck, O. Gluz, S. Kuemmel, 2019 .

Pattern of care of adjuvant radiotherapy in male breast cancer patients in clinical practice: an observational study

N. Harbeck, C. Belka, S. Corradini, 2018, Strahlentherapie und Onkologie.

Cost Analysis Comparing an Anthracycline/Docetaxel Regimen to CMF in Patients with Early Stage Breast Cancer

N. Harbeck, W. Kuhn, V. Jacobs, 2009, Oncology Research and Treatment.

Prediction of response to neoadjuvant chemotherapy in breast cancer patients by circulating apoptotic biomarkers nucleosomes, DNAse, cytokeratin-18 fragments and survivin.

V. Heinemann, O. Stoetzer, C. Gabka, 2013, Cancer letters.

Circulating immunogenic cell death biomarkers HMGB1 and RAGE in breast cancer patients during neoadjuvant chemotherapy

V. Heinemann, O. Stoetzer, C. Gabka, 2013, Tumor Biology.

Survival of de novo stage IV breast cancer patients over three decades

M. Kiechle, N. Harbeck, I. Bauerfeind, 2016, Journal of Cancer Research and Clinical Oncology.

Immune Markers and Tumor-Related Processes Predict Neoadjuvant Therapy Response in the WSG-ADAPT HER2-Positive/Hormone Receptor-Positive Trial in Early Breast Cancer

N. Harbeck, O. Gluz, S. Kuemmel, 2021, Cancers.

Enhancing adherence to capecitabine chemotherapy by means of multidisciplinary pharmaceutical care

Y. Ko, W. Kuhn, U. Jaehde, 2010, Supportive Care in Cancer.

Phase II trial of intravenous endotoxin in patients with colorectal and non-small cell lung cancer.

A. Mackensen, R. Mertelsmann, P. Schmid, 1996, European journal of cancer.

Distinguishing medullary carcinoma of the breast from high‐grade hormone receptor‐negative invasive ductal carcinoma: an immunohistochemical approach

H. Gevensleben, R. Schmutzler, R. Buettner, 2010, Histopathology.

Pharmaceutical care for patients with breast and ovarian cancer

W. Kuhn, U. Jaehde, T. Schink, 2012, Supportive Care in Cancer.

Who may benefit from preoperative breast MRI? A single-center analysis of 1102 consecutive patients with primary breast cancer

C. Kuhl, C. Leutner, H. Schild, 2015, Breast Cancer Research and Treatment.

Individual Factors Contributing to Nausea in First-Time Chemotherapy Patients: A Prospective Cohort Study

E. Olliges, K. Meissner, C. Salat, 2019, Front. Pharmacol..

Improved systemic treatment for early breast cancer improves cure rates, modifies metastatic pattern and shortens post-metastatic survival: 35-year results from the Munich Cancer Registry

M. Kiechle, N. Harbeck, I. Bauerfeind, 2017, Journal of Cancer Research and Clinical Oncology.

Evaluation of E-cadherin, Ki-67 and lymphatic vessel invasion in abdominal metastases of human breast cancer.

W. Kuhn, H. Schildhaus, P. Locher, 2013, Anticancer research.

Increased detection of lymphatic vessel invasion by D2-40 (podoplanin) in early breast cancer: possible influence on patient selection for accelerated partial breast irradiation.

K. Walgenbach, H. Schild, T. Höller, 2010, International journal of radiation oncology, biology, physics.

Radiation therapy and tamoxifen after breast-conserving surgery: updated results of a 2 x 2 randomised clinical trial in patients with low risk of recurrence.

W. Sauerbrei, K. Winzer, H. Guski, 2010, European journal of cancer.

Heart sparing radiotherapy in breast cancer: the importance of baseline cardiac risks

N. Harbeck, C. Belka, S. Corradini, 2020, Radiation oncology.

A Rare Complication Following Breast Implant Surgery: Capsular Contracture with a Cutaneous Silicone Fistula after Breast Reconstruction with Silicone Gel Implants

K. Walgenbach, C. Kuhl, W. Kuhn, 2011, Breast Care.

Quality of life in breast cancer patients and surgical results of immediate tissue expander/implant-based breast reconstruction after mastectomy

M. Hamann, M. Braun, H. Scheithauer, 2019, Archives of Gynecology and Obstetrics.

Mastectomy or Breast-Conserving Therapy for Early Breast Cancer in Real-Life Clinical Practice: Outcome Comparison of 7565 Cases

N. Harbeck, C. Belka, F. Alongi, 2019, Cancers.

In vivo intratumor angiogenic treatment effects during taxane-based neoadjuvant chemotherapy of ovarian cancer

T. Höller, R. Büttner, W. Kuhn, 2010, BMC Cancer.

Changes in Ki-67 Labeling Indices During Neoadjuvant Chemotherapy for Advanced Ovarian Cancer Are Associated With Survival

R. Fimmers, R. Büttner, W. Kuhn, 2009, International Journal of Gynecologic Cancer.

Neoadjuvant chemotherapy with carboplatin and docetaxel in advanced ovarian cancer--a prospective multicenter phase II trial (PRIMOVAR).

C. Leutner, W. Kuhn, O. Ortmann, 2009, Oncology reports.

Potential impact of preoperative magnetic resonance imaging of the breast on patient selection for accelerated partial breast irradiation.

C. Kuhl, C. Leutner, H. Schild, 2011, International journal of radiation oncology, biology, physics.

Radiation therapy after breast-conserving surgery; first results of a randomised clinical trial in patients with low risk of recurrence.

W. Sauerbrei, K. Winzer, H. Guski, 2004, European journal of cancer.

Adjuvant Therapy for Elderly Breast Cancer Patients after Breast-Conserving Surgery: Outcomes in Real World Practice

N. Harbeck, C. Belka, S. Corradini, 2023, Cancers.

Post-Neoadjuvant Gemcitabine and Cisplatin with Regional Hyperthermia for Patients with Triple-Negative Breast Cancer and Non-pCR after Neoadjuvant Chemotherapy: A Single-Institute Experience

U. Mansmann, N. Harbeck, O. Gluz, 2020, Breast Care.

Impact of RNA Signatures on pCR and Survival after 12-Week Neoadjuvant Pertuzumab plus Trastuzumab with or without Paclitaxel in the WSG-ADAPT HER2+/HR− Trial

F. Feuerhake, N. Harbeck, O. Gluz, 2022, Clinical Cancer Research.

De-escalated neoadjuvant pertuzumab+trastuzumab with or without paclitaxel weekly in HR-/HER2+ early breast cancer: ADAPT-HR-/HER2+ biomarker and survival results.

N. Harbeck, O. Gluz, S. Kuemmel, 2021 .

Abstract P4-10-05: Predictive value of HER2 expression, early response and tumor infiltrating lymphocytes (TILs) on efficacy of de-escalated pertuzumab+trastuzumab in the neoadjuvant WSG-ADAPT-HER2+/HR- trial

F. Feuerhake, N. Harbeck, O. Gluz, 2020 .

Association of molecular subtype, proliferation, and immune genes with efficacy of carboplatin versus gemcitabine addition to taxane-based, anthracycline-free neoadjuvant chemotherapy in early triple-negative breast cancer (TNBC): Results of the randomized WSG ADAPT-TN trial.

N. Harbeck, O. Gluz, C. Liedtke, 2017 .

Impact of PIK3CA mutation status on immune marker response and pCR in the WSG-ADAPT HER2+/HR+ phase II trial.

N. Harbeck, O. Gluz, C. Liedtke, 2018 .

Durvalumab improves long-term outcome in TNBC: results from the phase II randomized GeparNUEVO study investigating neodjuvant durvalumab in addition to an anthracycline/taxane based neoadjuvant chemotherapy in early triple-negative breast cancer (TNBC).

P. Fasching, A. Schneeweiss, C. Denkert, 2021, Journal of Clinical Oncology.

Role of postoperative radiotherapy in reducing ipsilateral recurrence in DCIS: an observational study of 1048 cases

N. Harbeck, C. Belka, S. Corradini, 2018, Radiation oncology.

[Magnetic resonance imaging in preoperative staging for breast cancer: pros and contras].

C. Kuhl, M. Braun, 2008, Der Radiologe.

Endometrial cancer—how many patients could benefit from sentinel lymph node dissection?

M. Hamann, M. Braun, M. Pölcher, 2018, World Journal of Surgical Oncology.

De-Escalated Neoadjuvant Trastuzumab-Emtansine With or Without Endocrine Therapy Versus Trastuzumab With Endocrine Therapy in HR+/HER2+ Early Breast Cancer: 5-Year Survival in the WSG-ADAPT-TP Trial

N. Harbeck, O. Gluz, S. Kümmel, 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Comparison of 12 weeks neoadjuvant Nab-Paclitaxel combined with Carboplatinum vs. Gemcitabine in triple negative breast cancer: WSG-ADAPT TN randomized phase II trial

N. Harbeck, O. Gluz, C. Liedtke, 2016 .

De-escalated neoadjuvant chemotherapy in early triple-negative breast cancer (TNBC): Impact of molecular markers and survival analysis of the WSG-ADAPT-TN trial.

N. Harbeck, O. Gluz, S. Kuemmel, 2022, Clinical cancer research : an official journal of the American Association for Cancer Research.

LBA14 De-escalated neoadjuvant T-DM1 with or without endocrine therapy (ET) vs trastuzumab+ET in early HR+/HER2+ breast cancer (BC): ADAPT-TP survival results

M. Hauptmann, N. Harbeck, S. Kuemmel, 2020 .

MRI-guided breast biopsy: influence of choice of vacuum biopsy system on the mode of biopsy of MRI-only suspicious breast lesions.

Christiane K. Kuhl, Simone Schrading, Hans H. Schild, 2010, AJR. American journal of roentgenology.

Abstract GS5-06: No survival benefit of chemotherapy escalation in patients with pCR and “high-immune” triple-negative early breast cancer in the neoadjuvant WSG-ADAPT-TN trial

F. Feuerhake, N. Harbeck, O. Gluz, 2019, General Session Abstracts.

Efficacy of 12-weeks of neoadjuvant TDM1 with or without endocrine therapy in HER2-positive hormone-receptor-positive early breast cancer: WSG-ADAPT HER2+/HR+ phase II trial.

N. Harbeck, O. Gluz, C. Liedtke, 2015 .

Concordance of the molecular subtype classification between core needle biopsy and surgical specimen in primary breast cancer

O. Stoetzer, M. Hamann, M. Braun, 2021, Archives of Gynecology and Obstetrics.